Skip to main content
. Author manuscript; available in PMC: 2015 Jun 24.
Published in final edited form as: J Urol. 2012 Feb 14;187(4):1228–1233. doi: 10.1016/j.juro.2011.11.086

Table 3.

Multivariate model predicting % fPSA

Change in Predicted %fPSA
Mean (95% CI)
p Value*
Age (per 5-yr increase) −0.3 (−0.5, −0.05) 0.021
Race/ethnicity: 0.048
  NonHispanic white 0 (reference)
  NonHispanic black −0.4 (−1.8, 0.9)
  Mexican-American −3.2 (−4.8, −1.7)
  Other −1.3 (−4.4, 1.7)
Smoking status: 0.015
  Current smoker −1.2 (−2.8, 0.4)
  Former smoker 1.2 (−0.1, 2.5)
  Never smoker 0 (reference)
BMI (per 5 kg/m2 increase) 0.0 (−0.6, 0.5) 0.926
Diabetes: 0.003
  No 0 (reference)
  Yes 3.8 (1.4, 6.2)
BPH: 0.145
  No 0 (reference)
  Yes −1.4 (−3.4, 0.5)
Statin use: 0.812
  No 0 (reference)
  Yes −0.2 (−1.6, 1.2)
NSAID use: 0.287
  No 0 (reference)
  Yes 1.2 (−1.0, 3.4)
Thiazide diuretic use: 0.151
  No 0 (reference)
  Yes 1.5 (−0.6, 3.7)
C-reactive protein Nonlinear (nonlinear) <0.001

All variables included in the model are shown in the table.

*

Based on the F-statistic with Satterthwaite correction for the degrees of freedom from the simultaneous test that all coefficients for a given variable are equal to 0.

Prescription only.

Increasing C-reactive protein was associated with a decrease in %fPSA for levels up to 0.7 mg/dl. Above this level there was no relationship between C-reactive protein and %fPSA.